p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis

Table 1 Studies included in the meta-analysis

Study	Year	Country	p53 (+)	p53 (−)	No. of patients	Cutoff (%)	Antibody	Intravesical therapy	Quality score
Park [21]	2013	Korea	32	29	61	10	DO7	Pure BCG	7
Dalbagni [14]	2007	USA	53	36	89	20	Pab1801	Non-pure	5.5
Saint [12]	2004	France	24	78	102	20	DO7	Pure BCG	6
Lopez-Beltran [29]	2004	Spain	22	29	51	6	Pab1801	Pure BCG	7
Gil [15]	2003	Spain	40	27	67	20	DO7	Non-pure	7
Peyromaure [22]	2002	France	18	11	29	20	DO7	Pure BCG	6
Liopis [13]	2000	Spain	24	56	80	20	Bp-53-12-1	Non-pure	8
Shariat [30]	2000	USA	26	10	36	10	DO7	Non-pure	7
Toktas [31]	1999	Turkey	18	34	36	10	DO7	Non-pure	6
Pages [23]	1998	France	27	16	43	10	DO7	Pure BCG	6
Vatne [32]	1995	Norway	40	19	59	20	DO1	Non-pure	7
Sarkis [8]	1993	USA	25	18	43	20	Pab1801	Non-pure	7

ISSN: 1477-7819